BMP2 inducible kinase (BMP2K)

BMP2 inducible kinase (BMP2K) is a serine/threonine kinase with high sequence similarity to adaptor-associated kinase 1 (AAK1), previously suspected of endocytic regulation[3]. Recent research shows BMP2K plays a critical role in erythroid maturation, specifically via regulation of autophagic degradation rather than classical endocytic trafficking[3]. The protein has two major splicing variants, BMP2K-L and BMP2K-S, which exert opposing effects on autophagy and erythropoiesis: BMP2K-L promotes autophagic degradation and erythroid maturation, whereas BMP2K-S inhibits them[3]. These isoforms interact with SEC16A, a regulator of COPII vesicle-mediated secretory trafficking, and likely modulate the assembly of autophagosomal and secretory machinery[3]. No evidence establishes this kinase, or its "BMP2KL" form, as a therapeutic target (receptor, enzyme, transporter, etc.) in clinical pharmacology. The term “BMP2KL” typically refers to “Putative BMP-2-inducible kinase-like protein,” which is a less common alias; canonical nomenclature in scientific literature is BMP2K[3]. There is also confusion with bone morphogenetic protein 2 (BMP-2), a separate TGF-β superfamily ligand involved in skeletal regulation, but BMP2K is not a receptor for BMP-2 and is not itself regarded as a receptor[1][2][3]. No clinically approved drugs are known to target BMP2K. The term “BMP2KL” appears rarely and seems to be a less accurate or non-standard designation for BMP2K, making "BMP2KL" likely incorrect as a canonical target name and "Putative BMP-2-inducible kinase-like protein" an outdated or rarely used synonym[3].

Other names

BMP2 inducible kinaseBMP2KLBMP2KPutative BMP-2-inducible kinase-like protein